PepGen Q3 2025 Earnings Report

PepGen EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.71
• Beat/Miss: N/A
• One Year Ago EPS: N/A

PepGen Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

PepGen Announcement Details

• Quarter: Q3 2025
• Date: 11/6/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, November 6, 2025
• Conference Call Time: 7:00AM ET

PepGen (NASDAQ:PEPG) (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome). These in vivo gene editing candidates are engineered to restore enzyme activity in affected tissues, potentially reducing the burden of repeated interventions. Beyond lysosomal storage disorders, PepGen is advancing earlier-stage research in inherited cardiovascular and metabolic conditions leveraging the same platform.

Founded in 2020 by a cohort of genome engineering scientists, PepGen has assembled an interdisciplinary team with expertise in translational research, clinical development and regulatory strategy. The company’s research operations are based in San Diego, where it maintains research laboratories and manufacturing collaborations. PepGen also partners with academic institutions and clinical centers across the United States to support preclinical studies and future clinical trial sites.

Under the leadership of Chief Executive Officer David Becker, who previously held senior roles at multiple biotechnology firms, PepGen is preparing its pipeline for regulatory interactions and human trials. The company has initiated strategic alliances to extend its capabilities in vector production and to explore commercialization pathways in North America and Europe.